Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8906942 | 0.98 | DUT (0.35) | DUT | |
| SCHEMBL4061244 | 0.98 | DUT (0.35) | DUT | |
| SCHEMBL8906883 | 0.98 | DUT (0.35) | DUT | |
| SCHEMBL3650896 | 0.98 | DUT (0.35) | DUT | |
| SCHEMBL3207889 | 0.98 | DUT (0.35) | DUT | |
| SCHEMBL23727498 | 0.98 | DUT (0.35) | DUT | |
| SCHEMBL7588597 | 0.98 | DUT (0.35) | DUT | |
| SCHEMBL5356889 | 0.98 | DUT (0.35) | DUT | |
| SCHEMBL4053845 | 0.98 | DUT (0.35) | DUT | |
| SCHEMBL1578618 | 0.96 | DUT (0.37) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0827423-B1 | FUNCTIONALIZED CHAIN EXTENDED INITIATORS FOR ANIONIC POLYMERIZATION | FMC CORP (US) | 2007-12-12 | — | — | EP | claimed |
| EP-2803358-B1 | 10,10-Dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure | ALLERGAN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9637467-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637467-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9334262-B2 | Methods of treating soft tissue defects | ALLERGAN, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334262-B2 | Methods of treating soft tissue defects | ALLERGAN, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20160096817-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALLERGAN, INC. | 2016-04-07 | — | — | US | disclosed |
| US-20160096817-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALLERGAN, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9156810-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156810-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-0871624-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | Merck & Co., Inc. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997021703-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-06-19 | — | — | WO | disclosed |
| US-5434186-A | Antiinflammatory agents | HOFFMANN-LA ROCHE INC. (US) | 1995-07-18 | — | — | US | disclosed |
| US-5273999-A | A 4-keto-boroalkyleneoxychroman or 2,3-dihydrobenzofuran derivative | HOFFMANN-LA ROCHE INC. (US) | 1993-12-28 | — | — | US | disclosed |
| EP-0531823-A1 | Bicyclic carboxylic acid derivatives as anti-inflammatory agents | F. HOFFMANN-LA ROCHE AG (CH) | 1993-03-17 | — | — | EP | disclosed |
| EP-0195379-B1 | ALLENIC PROSTACYCLINS | G.D. Searle & Co. (US) | 1991-04-03 | — | — | EP | disclosed |
| US-4761425-A | ANTIASTHMATICS; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1988-08-02 | — | — | US | disclosed |
| US-4754055-A | ANTICOAGULATNS, ATHEROSCEROSIS, ANTIALLERGENS, ANTIULCER AGENTS, HYPOTENSIVE AND ANTITUMOR AGENTS | G. D. SEARLE & CO. (US) | 1988-06-28 | — | — | US | disclosed |
| EP-0195379-A2 | Allenic prostacyclins | G.D. Searle & Co. (US) | 1986-09-24 | — | — | EP | disclosed |
| EP-0147217-A2 | Leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096817-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | SLC10A2, FABP2, LTB4R2 | DUT 1804/4885MAOA 1241/4885MAOB 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.